Podcast
Lung Cancer Update
Hosted by Dr. Neil Love · EN
Featuring one-on-one interviews conducted by Dr Neil Love, this series bridges the gap between research and patient care by providing medical oncologists, hematologists and hematology/oncology fellows ongoing access to the perspectives and opinions of national and international research leaders with an expertise in thoracic oncology.
33episodes
Episodes
Newest firstAll episodes
Small Cell Lung Cancer — Year in Review Series on Relevant New Datasets and Advances
Jun 900:58:47Tap to summarizeDr Christine L Hann from the Johns Hopkins University School of Medicine in Baltimore, Maryland, and Dr Jacob Sands from Dana-Farber Cancer Institute in Boston, Massachusetts, discuss key clinical trial data surrounding the management of SCLC.CME information and select publications
Transcribe →EGFR-Mutant Non-Small Cell Lung Cancer — Year in Review Series on Relevant New Datasets and Advances
Apr 2700:57:26Tap to summarizeDr Suresh S Ramalingam and Dr Helena Yu discuss the selection and sequencing of therapy for patients with EGFR mutation-positive non-small cell lung cancer and summarize major advances in the treatment landscape reported over the past year. CME information and select publications here.
Transcribe →Lung Cancer — 5-Minute Journal Club with Dr Natalie Vokes: Current and Future Role of Tumor-Informed Circulating Tumor DNA Assays
Apr 1700:27:12Tap to summarizeDr Natalie Vokes from The University of Texas MD Anderson Cancer Center in Houston discusses recent developments with circulating tumor DNA assays in the management of lung cancer. CME information and select publications here.
Transcribe →Extensive-Stage Small Cell Lung Cancer — Current Patterns of Care with First-Line and Maintenance Therapy
Feb 2700:59:42Tap to summarizeDr Hossein Borghaei from Fox Chase Cancer Center in Philadelphia, Pennsylvania, and Dr Anne Chiang from Yale Cancer Center in New Haven, Connecticut, discuss key clinical trial data in the first-line management of ES-SCLC, real-world case studies and current patterns of care among oncologists.CME information and select publications here.
Transcribe →Extensive-Stage Small Cell Lung Cancer — What Clinicians Want to Know About First-Line and Maintenance Therapy
Dec 1700:57:46Tap to summarizeDr Luis Paz-Ares from the Spanish National Oncology Research Center in Madrid and Dr Shields from Indiana University School of Medicine in Indianapolis discuss key datasets surrounding first-line and maintenance therapy for patients with extensive-stage small cell lung cancer and their clinical implications. CME information and select publications here.
Transcribe →Lung Cancer — Proceedings from a Symposium Held in Partnership with the American Oncology Network
Dec 1201:43:11Tap to summarizeDr Justin F Gainor, Dr Corey J Langer and Dr Misty Dawn Shields summarize the treatment landscape and review relevant clinical datasets for patients with lung cancer.CME information and select publications here.
Transcribe →HER2-Altered Non-Small Cell Lung Cancer — An Interview with Dr John V Heymach
Dec 1001:05:13Tap to summarizeDr John Heymach from The University of Texas MD Anderson Cancer Center in Houston discusses recent updates on available and novel treatment strategies for HER2-altered non-small cell lung cancer. CME information and select publications here.
Transcribe →Lung Cancer — 5-Minute Journal Club Issue 4 with Dr Aaron Lisberg: Defining the Role of TROP2-Directed Antibody-Drug Conjugates
Nov 1000:21:21Tap to summarizeDr Aaron Lisberg from the University of California, Los Angeles, discusses recent developments with TROP2-directed antibody-drug conjugates in the management of non-small cell lung cancer. CME information and select publications here.
Transcribe →Lung Cancer — 5-Minute Journal Club Issue 3 with Dr Aaron Lisberg: Defining the Role of TROP2-Directed Antibody-Drug Conjugates
Oct 2000:24:47Tap to summarizeDr Aaron Lisberg from the University of California, Los Angeles discusses recent developments with TROP2-directed antibody-drug conjugates in the management of non-small cell lung cancer. CME information and select publications here.
Transcribe →Non-Small Cell Lung Cancer — 5-Minute Journal Club Issue 2 with Dr Jacob Sands: Defining the Role of TROP2-Directed Antibody-Drug Conjugates
Sep 1400:23:19Tap to summarizeDr Jacob Sands from Dana-Farber Cancer Institute in Boston, Massachusetts, discusses recent developments with TROP2-directed antibody-drug conjugates in the management of lung cancer. CME information and select publications here.
Transcribe →